Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

華潤醫藥集團有限公司
China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

DISCLOSEABLE TRANSACTION
UPDATE ON PROPOSED ACQUISITION OF LIER CHEMICAL

Reference is made to the announcement (the "**Announcement**") of China Resources Pharmaceutical Group Limited (the "**Company**") dated 30 July 2026 in relation to the proposed acquisition of interest in Lier Chemical Group Co., Ltd. (利爾化學股份有限公司) ("**Lier Chemical**") by China Resources Double-Crane Pharmaceutical Co., Ltd. (華潤雙鶴藥業股份有限公司) ("**CR Double-Crane**"). Unless otherwise specified, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, the Share Purchase Agreement shall come into effect upon the fulfilment of conditions precedent set forth therein. If the conditions precedent are not fulfilled within 120 days from the date of the Share Purchase Agreement, and the parties have not reached an agreement to extend such period, the Share Purchase Agreement shall not come into effect and shall be terminated.

As at the date of this announcement, CR Double-Crane has paid the contract deposit representing 30% of the proposed consideration in accordance with the Share Purchase Agreement. Accordingly, the condition precedent set out in paragraph (e) under the section headed "The Proposed Acquisition — (5) Conditions precedent" in the Announcement has been satisfied. The parties are in the progress of fulfilling the remaining conditions precedent.

As additional time will be required for the fulfilment of the conditions precedent, the board of directors of CR Double-Crane has resolved for CR Double-Crane to enter into a supplemental agreement (the "**Supplemental Agreement**") with the Vendors, pursuant to which the parties agreed that the time for fulfilment of the conditions precedents set out in the Share Purchase Agreement shall be extended to 240 days from the date of the Share Purchase Agreement.

Save for the terms in the Supplemental Agreement, all other terms and conditions of the Share Purchase Agreement and the transactions contemplated thereunder shall remain unchanged and continue in full force and effect.

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 23 November 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Cheng Jie and Mr. Liu Changan as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mdm. Zhang Jing and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.